CG
CHRS icon

Cutler Group’s Coherus Oncology CHRS Stock Holding History

Cutler Group’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-4,100
Closed -$1K – 4067
2019
Q4 		$1K Buy
+4,100
New +$75.6K ﹤0.01% 3620
2017
Q3 		– Sell
-10,300
Closed -$3K – 5925
2017
Q2 		$3K Buy
10,300
+1,900
+23% +$36.5K ﹤0.01% 5205
2017
Q1 		$17K Buy
8,400
+6,300
+300% +$155K ﹤0.01% 3478
2016
Q4 		$3K Sell
2,100
-14,000
-87% -$392K ﹤0.01% 5266
2016
Q3 		$20K Buy
16,100
+4,400
+38% +$120K ﹤0.01% 3413
2016
Q2 		$4K Buy
11,700
+800
+7% +$15K ﹤0.01% 5094
2016
Q1 		$11K Buy
+10,900
New +$179K ﹤0.01% 3939

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Cutler Group's CHRS Position: Q3 2023 in Review

Cutler Group sold out of Coherus Oncology (CHRS) in Q3 2023, closing a stake of 2,000 shares — an estimated $8K sold.

Cutler Group first reported a position in CHRS in Q3 2016 and held it in 12 quarters. The position peaked at $211K in Q4 2016. 169 funds tracked by Wall St. Rank hold CHRS as of Q3 2023.

  • Cutler Group reported no remaining Coherus Oncology position as of Q3 2023 after selling out during the quarter.
  • Cutler Group sold 2,000 Coherus Oncology shares in Q3 2023, an estimated $8K.
  • Cutler Group first reported a position in Coherus Oncology in Q3 2016 and held it in 12 quarters.
  • Cutler Group's Coherus Oncology position peaked at $211K in Q4 2016.
  • 169 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2023.

Based on Cutler Group's 13F filing for Q3 2023, filed 7 Nov 2023.